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Strengths and limitations of this study
 ► This study investigated the safety of live zoster vac-
cination during immunosuppression in a large na-
tional cohort using electronic health records.
 ► It is the first study to cover the full profile of causes 
of immunosuppression listed as contraindications 
to vaccination in UK national guidance, ascertained 
from multiple primary and secondary care sources.
 ► Both primary and secondary care records were 
used for thorough ascertainment of varicella- zoster 
virus- related disease, including a sensitivity analysis 
ascertaining non- specific rash or encephalitis of un-
specified aetiology.
 ► Vaccination rates were analysed using only year of 
birth for age- eligibility, and so the denominator was 
adjusted for birth cohorts with partial eligibility.
 ► Immunosuppression was not distinguished accord-
ing to severity, but clinicians may have vaccinated 
selectively and caution would be needed in apply-
ing these findings outside of current vaccination 
practice.
AbStrACt
Objectives To investigate the safety of live attenuated 
varicella zoster vaccination when administered to 
immunosuppressed individuals.
Design Prospective observational cohort study.
Setting The study used anonymised data from the 
Clinical Practice Research Datalink (CPRD), comprising a 
representative sample of routinely collected primary care 
data in England between 2013 and 2017 and and linked 
Hospital Episode Statistics data.
Participants 168 767 individuals age- eligible for varicella 
zoster vaccination registered at a general practice in 
England contributing data to CPRD.
Main outcome measures Electronic health records 
indicating immunosuppression, zoster vaccination, 
diagnoses of specific varicella- zoster virus (VZV)- related 
disease and non- specific rash/encephalitis compatible 
with VZV- related disease.
results Between 1 September 2013 and 31 August 2017, 
a period of immunosuppression was identified for 9093/168 
767 (5.4%; 95% CI: 5.3%–5.5%) individuals age- eligible 
for zoster vaccination. The overall rate of vaccination while 
immunosuppressed was 1742/5251 (33.2 per 100 adjusted 
person years at risk; 95% CI: 31.9%–34.5%). Follow- up of 
the 1742 individuals who were inadvertently vaccinated 
while immunosuppressed identified only two cases of VZV- 
related disease within 8 weeks of vaccination (0.1%; 95% CI: 
0.01%–0.4%), both primary care diagnoses of ‘shingles’, 
neither with a related hospital admission.
Conclusions Despite evidence of inadvertent vaccination of 
immunosuppressed individuals with live zoster vaccination, 
there is a lack of evidence of severe consequences including 
hospitalisation. This should reassure primary care staff 
and encourage vaccination of mildly immunosuppressed 
individuals who do not meet current thresholds for 
contraindication. These findings support a review of the 
extent to which live zoster vaccination is contraindicated 
among the immunosuppressed.
IntrODuCtIOn
Herpes zoster (shingles) is a common and 
painful disease caused by reactivation of 
varicella- zoster virus (VZV), with debili-
tating complications including post- herpetic 
neuralgia. Live- attenuated zoster vaccine was 
introduced for immunocompetent adults aged 
70–79 years in England in 2013, delivered in 
primary care.1 The herpes zoster vaccination 
programme in England was found to have a 
population impact equivalent to approximately 
17 000 fewer episodes of herpes zoster and 
3300 fewer episodes of postherpetic neuralgia 
among 5.5 million eligible individuals in the 
first 3 years of the programme.2
Immunosuppression is associated with 
a high burden of zoster and its complica-
tions,3 4 and there have been calls to consider 
vaccination for this population.5 However, 
live zoster vaccine is currently contrain-
dicated in immunosuppression as it may 
cause VZV- related disease.1 High- profile case 
reports of fatal vaccine- related disease among 
severely immunosuppressed individuals have 
caused concern and may have contributed to 
declining vaccine coverage.6 7 Understanding 
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the safety of live vaccination during immunosuppression 
is important to support guidance on use of the vaccine, 
to ensure that individuals who can safely benefit from the 
vaccine are enabled to do so.
A new vaccine which is recombinant rather than 
containing live virus could offer a safer alternative 
for immunosuppressed individuals without the risk of 
vaccine- related disease, and has been found to be effec-
tive among patients with autologous haematopoietic stem 
cell transplantation.8 However, supplies are currently 
unable to meet global demands. The Joint Committee on 
Vaccination and Immunisation has recommended use of 
the recombinant vaccine for individuals with immunosup-
pression. Understanding the safety of live vaccination for 
typical causes of immunosuppression will be important to 
prioritise use of limited supplies of the new recombinant 
vaccine. When recombinant vaccine is used in cases for 
which live vaccine is contraindicated, this may introduce 
potential for confusion and it will be even more important 
to understand the consequences of inadvertent live vacci-
nation during immunosuppression.
This study aimed to investigate the frequency and 
consequences of live zoster vaccination during immuno-
suppression among a large UK cohort from 2013 to 2017.
MethODS
Data source
This study used anonymised data from the Clinical Prac-
tice Research Datalink (CPRD). The data include infor-
mation on year of birth, medical diagnoses (version 2 
Read codes), prescriptions and vaccinations. For 60% 
of individuals, records are prelinked to anonymised 
hospitalisation data (Hospital Episode Statistics, HES). 
HES- linked data for inpatient admissions (International 
Classification of Diseases, ICD-10 codes) and procedures 
(OPCS-4 Classification of Interventions and Procedures 
codes) were used to supplement identification of immu-
nosuppressed individuals and VZV- related disease.
Study population
Immunosuppressed individuals age- eligible for zoster 
vaccination, active in CPRD from September 2013 to 
August 2017 and registered with a CPRD practice for at 
least a year before study entry, were included.
Age eligibility for zoster vaccination has differed each 
year since the vaccination introduction. As month of birth 
was not available, individuals born in years for which ≥67% 
of the population would have been eligible for vaccination 
were included (online supplementary appendix A1). Birth 
cohorts were defined as ‘maiden cohorts’ in the first year 
for which they were age- eligible for vaccination.
Periods of immunosuppression were identified using 
Read codes and prescription records from CPRD, plus 
ICD-10 codes and OPCS codes in linked HES data using 
algorithms previously described.9 Immunosuppression 
was defined based on contraindications to live zoster 
vaccination described in national guidance.1 The time 
periods assigned to each immunosuppressing condition 
or medication type, and dose thresholds for relevant 
medications, are described in online supplementary 
appendix A2. For prescription records missing dose, the 
median was imputed according to category of age and 
sex, in line with previous zoster studies.4
Vaccination status and VZV-related disease
Individuals were followed to the first positive record of 
zoster vaccination. If this indicated that the vaccine was 
delivered by another healthcare provider the individual 
was excluded from the cohort, as timing of vaccination 
could not be determined (n=29).
Evidence of VZV- related disease in primary or secondary 
care records was assessed during the 8 weeks following 
a vaccination given while immunosuppressed. For the 
primary analysis, only specific diagnoses of VZV disease 
were included. Sensitivity analysis also included any rash 
that was unspecified or compatible with VZV, and acute 
encephalitis of unspecified aetiology. For individuals 
with HES- linkage, any diagnosis recorded within 8 weeks 
following vaccination was used to supplement identifi-
cation of VZV- related disease. Codelists are available at 
https:// datacompass. lshtm. ac. uk/ 1336/
Statistical methods
An open prospective cohort study design was used whereby 
individuals exited and re- entered the cohort according to 
time- varying immunosuppression status. Follow- up started 
on 1st September of the study year in which the individual 
was age- eligible for vaccination and ended at the earliest of 
death, date of transfer out of practice, practice last collec-
tion date, elapsed age- eligibility for zoster vaccination, reso-
lution of immunosuppression or 31 August 2017.
The vaccination rate was calculated by total person years 
at risk (PYAR) while immunosuppressed with adjustment 
to account for age- eligibility uncertainty from unknown 
month of birth (online supplementary appendix A1). 
Cumulative uptake of zoster vaccine was computed strati-
fied by treatment cohort and programme year.
The number of vaccinated immunosuppressed individ-
uals who developed VZV- related disease in the subsequent 
8 weeks was described. In sensitivity analysis, disease in the 
first week following vaccination was excluded.
Statistical analysis was performed using STATA V.14.2 
and SAS V.9.4.
Patient and public involvement
Patients and the public were not involved in the design or 
planning of the study.
reSultS
Between 1 September 2013 and 31 August 2017 data were 
available for 168 767 individuals age- eligible for vaccina-
tion, of whom 89 416 (53.0%) were female and 76 337 
(45.2%) in the catch- up cohort. A period of immunosup-
pression while age- eligible for vaccination was identified 
for 9093/168 767 (5.4%; 95% CI: 5.3%–5.5%).
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Figure 1 Cumulative uptake of zoster vaccination while 
immunosuppressed, by vaccination programme year. (A) 
Stratified by maiden years of eligibility or overall eligibility. (B) 
Stratified by routine or catch- up cohort.
One thousand seven hundred forty- two individuals 
were vaccinated during a period of immunosuppression. 
Adjusting PYAR while immunosuppressed to account for 
age- eligibility uncertainty, the overall rate of vaccination 
during immunosuppression was 1742/5251 (33.2 per 
100 adjusted PYAR; 95% CI: 31.9–34.5). Figure 1 shows 
the cumulative uptake of zoster vaccine by programme 
year overall, in maiden years of eligibility and by cohort. 
Cumulative uptake was higher in programme years 3 and 
4 when restricted to maiden years of eligibility. Cumula-
tive uptake was highest in programme years 1 and 2 for 
both the routine and catch- up cohorts.
Among those vaccinated while immunosuppressed, 
the most common underlying cause was chemotherapy 
(55.3%), followed by other immunosuppressant thera-
pies including biologics (13.2%), multiple indications 
(11.4%) and steroid drug use (11.3%). Forty seven 
(2.7%) had a permanent cause of immunosuppression; 
368 (21.1%) were immunosuppressed for the duration 
of follow- up; median follow- up 32.2 months (IQR: 19.7–
48.0). Vaccination took place during the final 4 weeks of 
a defined period of immunosuppression for 138/1742 
(7.9%).
In the 8 weeks following vaccination, 2/1742 (0.1%; 
95% CI: 0.01–0.4%) had a diagnosis of ‘shingles’ recorded 
in primary care. Both individuals had HES- linkage 
available; however, neither had a related hospital admis-
sion. One of these cases occurred within 7 days of 
vaccination.
Using a broader definition including non- specific rash 
or encephalitis identified a further 23 possible cases of 
VZV- related disease (in total 25/1742 (1.4%; 95% CI: 
0.9%–2.1%)). All of these were instances of unspecified 
rash in primary care, and there were no cases of enceph-
alitis. In total, 22/25 (88%) had HES- linkage available; 
however, none had a related hospital admission recorded. 
Five of the broader definition cases occurred within 7 
days of vaccine administration.
Chemotherapy was the cause of immunosuppres-
sion for the majority of cases who developed specific or 
non- specific potentially vaccine- related disease (15/25 
(60%)). The remaining cases included immunosuppres-
sion by oral steroid use, other immunosuppressant medi-
cations, leukaemia and organ transplant.
DISCuSSIOn
This is the first study to investigate the safety of live zoster 
vaccination across the range of contraindicating immu-
nosuppressive conditions. Our study identified 1742 
individuals vaccinated while immunosuppressed and two 
subsequent cases with a diagnosis of ‘shingles’, with no 
related hospitalisations, and no cases of encephalitis.
A key strength of this study is the thorough ascer-
tainment of both immunosuppression and VZV- related 
disease using linked primary and secondary care data for 
a large, representative cohort with a range of immuno-
suppressive conditions.
The study has limitations. A key limitation is that month 
of birth was not available for precise identification of age- 
eligibility. If immunosuppressed individuals in a birth 
cohort with 67% eligibility were vaccinated while not 
age- eligible, rates of vaccination in immunosuppression 
would be overestimated. There also remains uncertainty 
in defining time- periods of immunosuppression and in 
imputing missing dose data for medications which may 
result in underascertainment or overascertainment of 
immunosuppression.
It is possible that VZV- related disease may have been 
underascertained, either because patients did not 
attend healthcare or due to non- specific coding. A US 
study reported that 95% of patients aged over 60 years 
had attended healthcare when they experienced zoster 
disease,10 and this might be expected to be higher among 
immunosuppressed individuals in a setting with universal 
healthcare. This study used both primary care and 
secondary care records to ascertain VZV- related disease, 
an approach which has previously been found to generate 
plausible estimates of zoster incidence among the older 
general population.11 The sensitivity analysis was also 
designed to ascertain possible cases of VZV- related disease 
which may have been coded non- specifically as rash or 
encephalitis. Conversely, as this population has a high 
baseline risk of naturally occurring shingles, we may have 
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over- estimated the risk attributable to vaccination, partic-
ularly when including cases within 7 days of vaccination.
Finally, while our definitions of immunosuppression 
followed national guidance, we could not replace clinical 
judgement on severity or timing of immunosuppression, 
and the study was not powered to assess safety according 
to type of immunosuppression.1 Clinicians may have selec-
tively, rather than inadvertently, vaccinated individuals at 
lower risk of vaccine- related disease, resulting in a ‘healthy 
vaccinee’ effect, and caution would be needed in gener-
alising these findings outside of current practice in the 
context of guidance on contraindications. However, the 
most frequent contraindication was chemotherapy, and 
vaccinations did not occur disproportionately towards the 
end of a period of immunosuppression, suggesting that 
vaccinations were not all at the margins of the guidance.
Our safety findings are consistent with previous 
studies of live zoster vaccination among patients with 
selected immunosuppressive conditions.12–14 Studies 
showing that VZV- specific immunity may persist or even 
be boosted by vaccination during cell- mediated immu-
nosuppression,15–17 further support the plausibility of 
residual immunity against vaccine- related disease despite 
immunosuppression.
Rates of zoster vaccination during immunosuppres-
sion were high, and similar in routine and catch- up 
cohorts. To our knowledge, this is the first study to 
calculate rates of live zoster vaccination across this range 
of immunosuppressing conditions. A zoster vaccine 
effectiveness study of Medicare beneficiaries in the 
USA included 140 925 individuals with a diagnosis of 
leukaemia, lymphoma or HIV, of whom 4469 (3.2%) 
were vaccinated while immunosuppressed, comparable 
to the overall study vaccine uptake (29 785/766 330; 
3.9%), suggesting that live zoster vaccination despite 
immunosuppression is not unique to the UK setting.16 
In our study, analysis restricted to maiden years of eligi-
bility suggests that the apparent decline in vaccination 
rates after year 2 is partly a cohort effect, whereby people 
who were unvaccinated despite previous eligibility were 
less likely to be vaccinated subsequently. This could be 
due to an initial decision not to vaccinate continuing 
over subsequent years of eligibility, or a greater focus 
on vaccination for newly eligible patients. Increasingly 
detailed guidance over time may also have helped 
reduce inadvertent vaccination.
Among this large cohort with a range of immunosup-
pressing conditions, we found no evidence of severe VZV- 
related disease following live zoster vaccination while 
immunosuppressed. This should reassure clinicians, and 
encourage vaccination of mildly immunosuppressed indi-
viduals who do not meet current thresholds for contra-
indication, especially in the current context of declining 
uptake of the national programme.18 These findings 
support a review of the extent to which live zoster vacci-
nation is contraindicated among the immunosuppressed 
population. Further research is needed to identify any 
patient groups for whom recombinant zoster vaccine 
should be prioritised once stocks become available in the 
UK.
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